Most popular aesthetics stories of the week

A recent Health Affairs report on health care spending has created quite a stir. Our blogger, Lara Devgan, MD, MPH, offers her expert opinion on the reports’ implications for plastic surgery. Read on for more from Allergan and GC Aesthetics as well.

Allergan divests global generics business to Teva Pharma

Allergan announced that Teva Pharmaceuticals Industries Ltd. will acquire Allergan’s global generic pharmaceutical business for $40.5 billion. Read more

SurgiMend acellular dermal matrix has lower gross complication rate than Epiflex

In a head-to-head comparison of acellular dermal matrices in breast reconstruction, researchers preferred SurgiMend, which had fewer gross complications then Epiflex. Read more

GC Aesthetics launches IPO

The estimated price range isbetween $13 and $15 per share, according to the press release. Read more

Combining abdominal, cosmetic breast surgery does not increase short-term complication rates

Combining abdominal and breast procedures is safe in the majority of patients and does not increase 30-day complications rates, researchers found. Read more

Health care spending expected to increase over decade, but at historically low rate

Read the perspective on this issue from Lara Devgan, MD, MPH, “Cost containment is always an important consideration in developing a national budget. However, with the population growing in number, aging, and being diagnosed with more medical conditions (thanks to both more health care surveillance and a higher penetrance of health care among all demographics), it is surprising to see this slowed rate of growth.”